Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. SPY
5. ACN
6. IBM
7. PRIM
8. PFE
9. TSLA
10. DPZ

Go back to Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
(NASDAQ: IVVD) Delayed: 0.94 +0.03 (3.30%)
Previous Close $0.91    52 Week High $ 
Open $0.91    52 Week Low $ 
Day High $0.94    P/E N/A 
Day Low $0.90    EPS $ 
Volume 516,764       

(NASDAQ: IVVD) Delayed: 0.94 +0.03 (3.30%)
Previous Close $0.91    52 Week High $ 
Open $0.91    52 Week Low $ 
Day High $0.94    P/E N/A 
Day Low $0.90    EPS $ 
Volume 516,764